Research ArticleAccepted Articles
Open Access
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund and Anna-Birgitte Aga
The Journal of Rheumatology November 2022, jrheum.220645; DOI: https://doi.org/10.3899/jrheum.220645
Imane Bardan
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Karen Minde Fagerli
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Joe Sexton
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Tore K. Kvien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunnstein Bakland
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Pawel Mielnik
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Yi Hu
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunhild Lien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Berit Flatø
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Øyvind Molberg
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Eirik Klami Kristianslund
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Anna-Birgitte Aga
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Abstract
Objective Compare effectiveness of tumor necrosis factor inhibitors (TNFi) ± comedication and methotrexate monotherapy (MTX mono) between adult juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) patients.
Methods Adult JIA and RA patients were identified from the NOR-DMARD register. Disease activity measurements at baseline, 3, 6 and 12 months were compared between JIA and RA patients starting (1) TNFi and (2) MTX monotherapy, using age- and gender-weighted analyses. We calculated differences between JIA and RA in mean changes in DAS28, CDAI and SDAI, among other disease activity measures. DAS28, CDAI, SDAI and ACR/EULAR remission rates at 3, 6 and 12 months, as well as 6- and 12-month LUNDEX-corrected rates, were calculated.
Results We identified 478 JIA patients (TNFi/MTX mono N=358/120) and 4637 RA patients (N=2292/2345). JIA patients had lower baseline disease activity compared to RA patients across treatment groups. After baseline disease activity adjustment there were no significant differences in disease activity change from baseline to 3, 6 and 12-months follow-up between JIA and RA patients for either treatment group. 12- month remission rates were similar between groups based on DAS28 (TNFi: JIA 55.2%, RA 49.5%. MTX mono: JIA 45.3%, RA 41.2%) and ACR/EULAR remission criteria (TNF: JIA 20.4%, RA 20.0%. MTX mono: JIA 17.0%, RA 12.7%). Median drug survival (years) was similar for JIA and RA in both treatment groups (TNFi: JIA 1.2, RA 1.4; MTX mono: JIA 1.3, RA 1.6)
Conclusion TNFi and MTX mono are effective in adult JIA, with similar effectiveness as in RA.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 12
1 Dec 2022
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645
